---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-26-000046"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2026-08-06T20:09:05+00:00"
generated_at: "2026-08-06T20:11:58.317870+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zymeworks Q2 net loss $45M; PDUFA for zanidatamab Aug 25; Theravance acquisition on track

## Summary
- Net loss of $45.0M in Q2 2026 vs net income of $2.3M in Q2 2025; revenue fell to $4.6M from $48.7M.
- Cash and marketable securities $322.5M as of June 30, 2026; repurchased $49.4M of shares under new $125M program.
- PDUFA target date Aug 25, 2026 for zanidatamab in 1L HER2+ GEA; potential $250M U.S. approval milestone.
- Acquisition of Theravance Biopharma expected to close 2H 2026, adding YUPELRI profit share and ~$60M annualized cash flow.
- R&D expenses down 20% YoY to $27.4M; G&A up to $19.3M on higher stock comp.

## SEC filing metadata
- accession: 0001937653-26-000046
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2026-08-06T20:09:05+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/0001937653-26-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/zyme-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-26-000046
- JSON: https://secwatch.observer/filing/0001937653-26-000046.json
- Plain text: https://secwatch.observer/filing/0001937653-26-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.